- Resource
- Source: Campus Sanofi
- 23 Oct 2023
Praluent® (alirocumab) Patient profiles
![](https://pro.campus.sanofi/.imaging/mte/portal/3840/dam/Portal/UK/Patient-Supports/patient-profile-hero.jpg/jcr:content/patient-profile-hero.jpg)
![Praluent logo](https://pro.campus.sanofi/.imaging/mte/portal/3840/dam/Portal/UK/Articles/praluent_registered_4c_left_triangle_notag.png/jcr:content/praluent_registered_4c_left_triangle_notag.png)
Second MI
6 weeks ago
Age: 55 years
LDL-C: 3.6 mmol/L
Polyvascular disease (CAD & PAD)
Smoker
![Praluent Patient Profile 1](https://pro.campus.sanofi/.imaging/mte/portal/3840/dam/Portal/UK/Patient-Supports/1pp.png/jcr:content/1pp.png)
First MI
6 months ago
Age: 63 years
LDL-C: 4.1 mmol/L
No additional comorbidities or family history of heart disease
Non-smoker
![Praluent Patient Profile 3](https://pro.campus.sanofi/.imaging/mte/portal/3840/dam/Portal/UK/Patient-Supports/3pp.png/jcr:content/3pp.png)
First MI
12 months ago
Age: 63 years
LDL-C: 5.0 mmol/L
Familial hypercholesterolaemia
Non-smoker
![Praluent Patient Profile 2](https://pro.campus.sanofi/.imaging/mte/portal/3840/dam/Portal/UK/Patient-Supports/2pp.png/jcr:content/2pp.png)
Any ACS means the patient is at very high CV risk, regardless of comorbidities1
Praluent®
Find more information on Indication, Administration and Mechanism of Action and watch videos about Praluent®.
![](https://pro.campus.sanofi/.imaging/mte/portal/3840/dam/Portal/UK/Articles/Dyslipidaemia/unmet-needs/Image/Group-44.jpg/jcr:content/Group%2044.jpg)
![](https://pro.campus.sanofi/.imaging/mte/portal/3840/dam/Portal/UK/Articles/MicrosoftTeams-image--2---1-.jpg0/jcr:content/MicrosoftTeams-image%20(2)%20(1).jpg)
References
- March F, et al.2019 ESC/EAS Guidelines for the management of dyslipidaemias; lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41:111-188.
MAT-XU-2204602 (v7.0) Date of Preparation: February 2024